iBio, Inc.
iBio is a biotechnology company focused on developing next-generation therapeutics for obesity, diabetes, cardiometabolic diseases, and difficult-to-treat cancers. They leverage AI and machine learning in their drug discovery platform to identify and optimize antibody-based therapeutics. Their mission is to deliver impactful medicines to underserved patients, emphasizing innovation, collaboration, and integrity. The company is actively expanding its pipeline with high-value therapeutic candidates and collaborates with partners like AstralBio and others to advance drug discovery.
Industries
Nr. of Employees
small (1-50)
iBio, Inc.
11750 Sorrento Valley Road, Suite 200, San Diego, CA 92121
Patents
In vivo de-glycosylation of recombinant proteins by co-expression with PNGase F
US-11673926-B2
View DetailsMachine learning method for protein modelling to design engineered peptides
US-11545238-B2
View Details
In vivo de-glycosylation of recombinant proteins by co-expression with PNGase F
US-11673926-B2
View DetailsMachine learning method for protein modelling to design engineered peptides
US-11545238-B2
View DetailsProducts
AI-driven antibody discovery platform
An integrated technology stack combining epitope engineering, a proprietary human antibody library, optimization workflows, bispecific design tools, and masking technology to discover precision antibodies for difficult targets.
Myostatin-blocking antibody (preclinical, partner phase)
A long-acting antibody candidate targeting myostatin intended to increase lean mass and reduce fat mass; described as being available in a partner development phase.
Activin E-blocking antibody (IND‑enabling)
An antibody candidate designed to block Activin E with a proposed mechanism to promote fat-selective weight loss and lower cardiometabolic risk; described as being in an IND‑enabling phase.
Myostatin x Activin A bispecific antibody (lead optimization)
A bispecific antibody candidate engineered to simultaneously inhibit myostatin and Activin A to enhance muscle growth and improve weight-loss quality; described as being in lead optimization.
Amylin receptor antibody agonist (early discovery)
An engineered antibody agonist targeting the amylin receptor intended to modulate appetite control pathways distinct from GLP‑1 receptor agonists; described as being in early discovery.
IL‑2-sparing anti-CD25 antibody (IND‑enabling, oncology)
An antibody candidate designed to selectively deplete immunosuppressive regulatory T cells while sparing effector T cells, described in an IND‑enabling phase for solid tumors and select hematologic indications.
AI-driven antibody discovery platform
An integrated technology stack combining epitope engineering, a proprietary human antibody library, optimization workflows, bispecific design tools, and masking technology to discover precision antibodies for difficult targets.
Myostatin-blocking antibody (preclinical, partner phase)
A long-acting antibody candidate targeting myostatin intended to increase lean mass and reduce fat mass; described as being available in a partner development phase.
Activin E-blocking antibody (IND‑enabling)
An antibody candidate designed to block Activin E with a proposed mechanism to promote fat-selective weight loss and lower cardiometabolic risk; described as being in an IND‑enabling phase.
Myostatin x Activin A bispecific antibody (lead optimization)
A bispecific antibody candidate engineered to simultaneously inhibit myostatin and Activin A to enhance muscle growth and improve weight-loss quality; described as being in lead optimization.
Amylin receptor antibody agonist (early discovery)
An engineered antibody agonist targeting the amylin receptor intended to modulate appetite control pathways distinct from GLP‑1 receptor agonists; described as being in early discovery.
IL‑2-sparing anti-CD25 antibody (IND‑enabling, oncology)
An antibody candidate designed to selectively deplete immunosuppressive regulatory T cells while sparing effector T cells, described in an IND‑enabling phase for solid tumors and select hematologic indications.
Services
Licensing of an integrated AI-driven antibody discovery platform or collaboration to apply platform capabilities to partner targets and co-develop therapeutic candidates.
Licensing of an integrated AI-driven antibody discovery platform or collaboration to apply platform capabilities to partner targets and co-develop therapeutic candidates.
Expertise Areas
- Antibody discovery and engineering
- Bispecific antibody design and optimization
- Antibody humanization and developability optimization
- Preclinical development and IND-enabling studies
Key Technologies
- AI / machine learning for drug discovery
- Epitope engineering and mini-protein epitope mimetics
- Human antibody sequence libraries
- Antibody humanization / optimization algorithms
News & Updates
April 8, 2024: iBio and AstralBio announced a collaboration on obesity drug discovery.
April 8, 2024: iBio and AstralBio announced a collaboration on obesity drug discovery.